Nesvacumab: Difference between revisions
Content deleted Content added
Anypodetos (talk | contribs) MAB data |
Anypodetos (talk | contribs) Some update |
||
| Line 16: | Line 16: | ||
| legal_UK = |
| legal_UK = |
||
| legal_US = |
| legal_US = |
||
| legal_status = |
| legal_status = Investigational |
||
| routes_of_administration = |
| routes_of_administration = |
||
| bioavailability = |
| bioavailability = |
||
| Line 34: | Line 34: | ||
| molecular_weight = 144.9 kg/mol |
| molecular_weight = 144.9 kg/mol |
||
}} |
}} |
||
'''Nesvacumab''' is |
'''Nesvacumab''' is an experimental [[monoclonal antibody]] originally designed for the treatment of cancer. It targets the protein [[angiopoietin 2]].<ref>[http://www.ama-assn.org/resources/doc/usan/nesvacumab.pdf Statement On A Nonproprietary Name Adopted By The USAN Council - Nesvacumab], ''[[American Medical Association]]''.</ref> {{as of|2017|5}}, it is in [[Phase II clinical trial]]s for the treatment of [[diabetic macular edema]].<ref>{{clinicalTrialsGov|NCT02713204|Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX)}}</ref><ref>{{clinicalTrialsGov|NCT02712008|Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema (RUBY)}}</ref> |
||
This drug |
This drug is being developed by [[Regeneron]] Pharmaceuticals. |
||
== References == |
== References == |
||
| Line 46: | Line 46: | ||
| ⚫ | |||
[[Category:Monoclonal antibodies]] |
[[Category:Monoclonal antibodies]] |
||
[[Category:Experimental cancer drugs]] |
[[Category:Experimental cancer drugs]] |
||
| ⚫ | |||
Revision as of 08:11, 1 May 2017
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Angiopoietin 2 |
| Clinical data | |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| IUPHAR/BPS | |
| ChemSpider |
|
| KEGG | |
| Chemical and physical data | |
| Formula | C6440H9966N1722O2008S38 |
| Molar mass | 144.9 kg/mol g·mol−1 |
Nesvacumab is an experimental monoclonal antibody originally designed for the treatment of cancer. It targets the protein angiopoietin 2.[1] As of May 2017[update], it is in Phase II clinical trials for the treatment of diabetic macular edema.[2][3]
This drug is being developed by Regeneron Pharmaceuticals.
References
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Nesvacumab, American Medical Association.
- ^ Clinical trial number NCT02713204 for "Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX)" at ClinicalTrials.gov
- ^ Clinical trial number NCT02712008 for "Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema (RUBY)" at ClinicalTrials.gov
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |